Antibody-Based Cancer Immunotherapy - Episode 22
For High-Definition, Click
Although not commonly used, interferon could soon be undergoing a renaissance for patients with renal cell carcinoma (RCC), believes Nicholas J. Vogelzang, MD. This treatment is still commonly used in Japan and will soon be combined with PD-1 inhibitors in clinical trials. It seems likely that interferon will once again have a role for patients with RCC, Vogelzang suggests.